National Cancer Institute (NCI): Breast Carcinoma In Situ trials
The registry lists 11 Breast Carcinoma In Situ studies with National Cancer Institute (NCI) as lead sponsor. 3 are open to participants now and 5 have results posted.
Phase 1 4Phase 2 5Phase 3 1No phase 1(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Low Dose Tamoxifen With or Without Omega-3 Fatty Acids for Breast Cancer Risk ReductionRecruitingNCT06195306Phase 2
- Finding the Best Tamoxifen Dose for Breast Cancer Risk Reduction in Premenopausal Women, RENAISSANCE TrialRecruitingNCT06184750Phase 2
- Acolbifene Versus Low Dose Tamoxifen for the Prevention of Breast Cancer in Premenopausal Women at High Risk for Development of Breast CancerRecruitingNCT05941520Phase 2
- Bexarotene in Preventing Breast Cancer in Patients at High Risk for Breast CancerCompletedNCT03323658Phase 1Results posted
- Phase I Trial of Endoxifen Gel Versus Placebo in Women Undergoing Breast SurgeryActive, not recruitingNCT03317405Phase 1Results posted
- Alternative Dosing of Exemestane Before Surgery in Treating Postmenopausal Patients With Stage 0-II Estrogen Positive Breast CancerCompletedNCT02598557Phase 2Results posted
- Study of Docosahexaenoic Acid (DHA) in Triple Negative Breast Cancer SurvivorsCompletedNCT01849250Phase 2Results posted
- Lapatinib Ditosylate in Treating Patients With Ductal Breast Carcinoma In SituCompletedNCT00555152Not applicableResults posted
- Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast CancerActive, not recruitingNCT02954874Phase 3
- Letrozole in Preventing Breast Cancer in Healthy Postmenopausal Women at High Risk for Breast CancerCompletedNCT01077453Phase 1
- A Phase I Prevention Study of Atorvastatin in Women at Increased Risk for Breast CancerCompletedNCT00637481Phase 1